Compare Stocks: ALZN, RNAZ, BRNS, and BCTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALZN Alzamend Neuro	$1.72 +1.2%	$1.44	$0.84 ▼ $2.68	$8.30M	0.23	107,970 shs	393,466 shs
BCTX Briacell Therap	$3.63 +0.8%	$3.62	$2.60 ▼ $14.68	$31.58M	1.1	607,432 shs	74,690 shs
BRNS Barinthus Biotherapeutics	$0.74	$0.64	$0.51 ▼ $1.83	$30.23M	-0.37	83,130 shs	N/A
RNAZ TransCode Therapeutics	$1.69	$4.68	$1.63 ▼ $20.99	$28.61M	1.16	87,451 shs	11,442 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALZN Alzamend Neuro	0.00%	+3.61%	+17.81%	+42.15%	-26.81%
BCTX Briacell Therap	0.00%	+1.68%	+5.52%	+31.05%	-53.16%
BRNS Barinthus Biotherapeutics	0.00%	-2.50%	+23.35%	+10.28%	-32.73%
RNAZ TransCode Therapeutics	0.00%	-17.96%	-51.44%	-68.29%	-84.21%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALZN Alzamend Neuro	$1.72 +1.2%	$1.44	$0.84 ▼ $2.68	$8.30M	0.23	107,970 shs	393,466 shs
BCTX Briacell Therap	$3.63 +0.8%	$3.62	$2.60 ▼ $14.68	$31.58M	1.1	607,432 shs	74,690 shs
BRNS Barinthus Biotherapeutics	$0.74	$0.64	$0.51 ▼ $1.83	$30.23M	-0.37	83,130 shs	N/A
RNAZ TransCode Therapeutics	$1.69	$4.68	$1.63 ▼ $20.99	$28.61M	1.16	87,451 shs	11,442 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALZN Alzamend Neuro	0.00%	+3.61%	+17.81%	+42.15%	-26.81%
BCTX Briacell Therap	0.00%	+1.68%	+5.52%	+31.05%	-53.16%
BRNS Barinthus Biotherapeutics	0.00%	-2.50%	+23.35%	+10.28%	-32.73%
RNAZ TransCode Therapeutics	0.00%	-17.96%	-51.44%	-68.29%	-84.21%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALZN Alzamend Neuro	2.00	Hold	$28.00	1,527.91% Upside
BCTX Briacell Therap	1.00	Sell	N/A	N/A
BRNS Barinthus Biotherapeutics	2.00	Hold	$4.00	440.54% Upside
RNAZ TransCode Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ALZN, RNAZ, BRNS, and BCTX Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/8/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/31/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
8/26/2026	BRNS Barinthus Biotherapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/25/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/11/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/21/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/20/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/17/2026	BCTX Briacell Therap	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	RNAZ TransCode Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	$0.19 per share	N/A
BCTX Briacell Therap	N/A	N/A	N/A	N/A	$9.20 per share	N/A
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	$1.82 per share	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	$11.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALZN Alzamend Neuro	-$8.77M	-$2.30	N/A	N/A	N/A	N/A	-374.26%	-243.39%	N/A
BCTX Briacell Therap	-$26.31M	-$7.92	N/A	N/A	N/A	N/A	-153.53%	-129.26%	N/A
BRNS Barinthus Biotherapeutics	-$66.43M	-$1.03	N/A	N/A	N/A	N/A	-59.15%	-43.80%	11/6/2026 (Estimated)
RNAZ TransCode Therapeutics	-$34.66M	-$52.37	N/A	N/A	N/A	N/A	-875.35%	-37.46%	11/18/2026 (Estimated)

Latest ALZN, RNAZ, BRNS, and BCTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2026	Q1 2027	ALZN Alzamend Neuro	-$0.56	-$0.68	-$0.12	-$0.68	N/A	N/A
8/14/2026	Q2 2026	RNAZ TransCode Therapeutics	N/A	-$7.17	N/A	-$7.17	N/A	N/A
8/7/2026	Q2 2026	BRNS Barinthus Biotherapeutics	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A
7/22/2026	Q4 2026	ALZN Alzamend Neuro	-$0.67	-$0.74	-$0.07	-$0.74	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	N/A
BCTX Briacell Therap	N/A	N/A	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALZN Alzamend Neuro	N/A	1.31	1.31
BCTX Briacell Therap	N/A	7.07	7.07
BRNS Barinthus Biotherapeutics	N/A	5.54	5.54
RNAZ TransCode Therapeutics	N/A	1.97	1.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALZN Alzamend Neuro	49.61%
BCTX Briacell Therap	15.42%
BRNS Barinthus Biotherapeutics	25.20%
RNAZ TransCode Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ALZN Alzamend Neuro	1.39%
BCTX Briacell Therap	0.74%
BRNS Barinthus Biotherapeutics	8.50%
RNAZ TransCode Therapeutics	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALZN Alzamend Neuro	4	4.83 million	4.76 million	No Data
BCTX Briacell Therap	8	8.70 million	8.64 million	No Data
BRNS Barinthus Biotherapeutics	107	40.85 million	37.38 million	N/A
RNAZ TransCode Therapeutics	9	16.93 million	16.91 million	Not Optionable

ALZN, RNAZ, BRNS, and BCTX Headlines

Recent News About These Companies

TransCode Therapeutics Announces Leadership Transition

September 10 at 4:10 PM | prnewswire.com

Join TransCode Therapeutics’ Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer

September 3, 2026 | usatoday.com

TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis

August 31, 2026 | prnewswire.com

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

August 7, 2026 | finance.yahoo.com

TransCode Therapeutics, Inc.

July 22, 2026 | edition.cnn.com

TransCode Therapeutics Inc RNAZ

July 3, 2026 | morningstar.comM

TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript

June 18, 2026 | seekingalpha.com

RNAZ: Introducing RNA therapeutics

June 8, 2026 | msn.com

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

June 8, 2026 | prnewswire.com

RNAZ Share News Today

June 4, 2026 | uk.investing.com

EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study

June 3, 2026 | finance.yahoo.com

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer

June 3, 2026 | prnewswire.com

TransCode Therapeutics, Inc.: TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

May 28, 2026 | finanznachrichten.de

TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

May 27, 2026 | prnewswire.com

TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University

April 27, 2026 | prnewswire.com

TransCode Therapeutics signs financing deal worth up to $20 million

April 8, 2026 | msn.com

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

April 7, 2026 | prnewswire.com

TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

March 3, 2026 | prnewswire.com

TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development

February 23, 2026 | prnewswire.com

TransCode Therapeutics Advances Phase 2a Colorectal Cancer Trial

February 11, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN, RNAZ, BRNS, and BCTX Company Descriptions

Alzamend Neuro NASDAQ:ALZN

$1.72 +0.02 (+1.18%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.72 0.00 (0.00%)

As of 09/11/2026 07:59 PM Eastern

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Briacell Therap NASDAQ:BCTX

$3.63 +0.03 (+0.83%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.66 +0.04 (+0.96%)

As of 09/11/2026 07:54 PM Eastern

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Barinthus Biotherapeutics NASDAQ:BRNS

$0.74 0.00 (0.00%)

As of 09/11/2026

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

TransCode Therapeutics NASDAQ:RNAZ

$1.69 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.69 0.00 (0.00%)

As of 09/11/2026 07:30 PM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALZN, RNAZ, BRNS, and BCTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALZN, RNAZ, BRNS, and BCTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALZN, RNAZ, BRNS, and BCTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN, RNAZ, BRNS, and BCTX Company Descriptions

Alzamend Neuro NASDAQ:ALZN

Briacell Therap NASDAQ:BCTX

Barinthus Biotherapeutics NASDAQ:BRNS

TransCode Therapeutics NASDAQ:RNAZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALZN, RNAZ, BRNS, and BCTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALZN, RNAZ, BRNS, and BCTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALZN, RNAZ, BRNS, and BCTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN, RNAZ, BRNS, and BCTX Company Descriptions

Alzamend Neuro NASDAQ:ALZN

Briacell Therap NASDAQ:BCTX

Barinthus Biotherapeutics NASDAQ:BRNS

TransCode Therapeutics NASDAQ:RNAZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools